Table 4.
Patients with CKD grouped according to plasma aldosterone concentration in the observational study.
| Q1 n = 28 | Q2 n = 29 | Q3 n = 27 | Q4 n = 28 | Q5 n = 29 | P | |
|---|---|---|---|---|---|---|
| PAC, ng/dL | 3.2–8.5 | 8.6–11.9 | 12.0–14.4 | 14.5–19.9 | 20.5–44.8 | P < 0.0001 |
| 6.20 ± 0.29 | 10.5 ± 0.20 | 13.0 ± 0.16 | 17.1 ± 0.32 | 26.7 ± 1.22 | ||
| Age | 66.3 ± 2.6 | 64.8 ± 2.2 | 62.4 ± 2.8 | 59.8 ± 2.5 | 61.9 ± 3.1 | P = 0.453 |
| Gender, male/female | 12/16 | 10/19 | 17/10 | 16/12 | 18/11 | P = 0.0376 |
| Baseline eGFR, ml/min/1.73 m2 | 62.2 ± 3.7 | 60.7 ± 3.2 | 59.3 ± 4.6 | 49.9 ± 3.1 | 54.0 ± 3.3 | P = 0.098 |
| Urinary protein, g/g creatinine | 0.136 ± 0.065 | 0.192 ± 0.098 | 0.509 ± 0.281 | 0.526 ± 0.199 | 0.406 ± 0.163 | P = 0.385 |
| Urinary albumin, mg/g creatinine | 83.1 ± 43.5 | 30.5 ± 10.4 | 34.3 ± 17.3 | 141.7 ± 57.1 | 126.8 ± 52.0 | P = 0.168 |
Urinary markers are normalized by urinary creatinine concentration. Values are expressed as mean ± SEM
CKD, chronic kidney disease; eGFR, estimated glomerular filtration rate; PAC, plasma aldosterone concentration; Q, quartile; SEM, standard error of the mean.